Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Niessner

Showing results (11-20 of 207) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|July 9, 2020
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve ReplacementStefan Stojkovic, Patrick Sulzgruber, Alexander Niessner
Cardiovascular Drugs and Therapy|May 25, 2023
Rivaroxaban in Valvular Atrial Fibrillation - a Critical Appraisal of the INVICTUS TrialAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|September 18, 2021
The impact of CD4<sup>+</sup>CD28<sup>null</sup> T lymphocytes on atrial fibrillation: a potential pathophysiological pathwayAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
The New England Journal of Medicine|January 10, 2024
Bifurcation-Lesion PCI Guided by OCT or AngiographyEva Steinacher, Lorenz Koller, Alexander Niessner
ESC Heart Failure|October 8, 2023
Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?Andreas Hammer, Alexander Niessner, Patrick Sulzgruber
The New England Journal of Medicine|November 30, 2022
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial FibrillationAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
The New England Journal of Medicine|June 28, 2023
Statin Intolerance, Bempedoic Acid, and Cardiovascular OutcomesEva Steinacher, Patrick Sulzgruber, Alexander Niessner
Cardiovascular Drugs and Therapy|February 13, 2023
Surgical or Percutaneous Coronary Revascularization for Heart Failure: a Focus on Symptoms and StenosisPatrick Sulzgruber, Ulrike Baumer, Alexander Niessner
Cardiovascular Drugs and Therapy|October 12, 2023
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal ProtectionAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
Cardiovascular Drugs and Therapy|June 14, 2022
Rivaroxaban After Transcatheter Aortic Valve Replacement: A Critical Appraisal of the GALILEO TrialPatrick Sulzgruber, Andreas Hammer, Alexander Niessner
Pageof 21

Showing results (11-20 of 207) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|July 9, 2020
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve ReplacementStefan Stojkovic, Patrick Sulzgruber, Alexander Niessner
Cardiovascular Drugs and Therapy|May 25, 2023
Rivaroxaban in Valvular Atrial Fibrillation - a Critical Appraisal of the INVICTUS TrialAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|September 18, 2021
The impact of CD4<sup>+</sup>CD28<sup>null</sup> T lymphocytes on atrial fibrillation: a potential pathophysiological pathwayAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
The New England Journal of Medicine|January 10, 2024
Bifurcation-Lesion PCI Guided by OCT or AngiographyEva Steinacher, Lorenz Koller, Alexander Niessner
ESC Heart Failure|October 8, 2023
Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?Andreas Hammer, Alexander Niessner, Patrick Sulzgruber
The New England Journal of Medicine|November 30, 2022
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial FibrillationAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
The New England Journal of Medicine|June 28, 2023
Statin Intolerance, Bempedoic Acid, and Cardiovascular OutcomesEva Steinacher, Patrick Sulzgruber, Alexander Niessner
Cardiovascular Drugs and Therapy|February 13, 2023
Surgical or Percutaneous Coronary Revascularization for Heart Failure: a Focus on Symptoms and StenosisPatrick Sulzgruber, Ulrike Baumer, Alexander Niessner
Cardiovascular Drugs and Therapy|October 12, 2023
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal ProtectionAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
Cardiovascular Drugs and Therapy|June 14, 2022
Rivaroxaban After Transcatheter Aortic Valve Replacement: A Critical Appraisal of the GALILEO TrialPatrick Sulzgruber, Andreas Hammer, Alexander Niessner
Pageof 21